<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fourteen patients with American Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> resistant to conventional chemotherapy were treated with high-dose combination chemotherapy and intensive supportive care </plain></SENT>
<SENT sid="1" pm="."><plain>Four patients died shortly after chemotherapy, 3 of an <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0001853'>carditis</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> ten remaining patients demonstrated <z:mp ids='MP_0010537'>tumor regression</z:mp> and 3 remain in prolonged complete unmaintained remission 29+, 19+, and 9+ months after treatment </plain></SENT>
<SENT sid="3" pm="."><plain>These findings demonstrate that high-dose chemotherapy will benefit some patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> unresponsive to conventional chemotherapy, but the medullary and extramedullary toxicity of this treatment strategy remains a formidable obstacle </plain></SENT>
</text></document>